Female, % 28 12.2 0.01 Diabetes Mellitus, % 11 4.9 0.15 Symptom onset to balloon time, min 172Ϯ64 161Ϯ61 0.27 Final corrected TIMI frame count 20.6Ϯ7.4 23.2Ϯ12.7 0.13 Final blush score 2 or 3, % 81.7 88.9 0.2 Relative ST segment resolution, % 72.8 [42.3, 85.3] 72.8 [57.7, 88.0] 0.56 LVEF change from baseline to follow-up, % 7.6Ϯ5.0 Ϫ3.0Ϯ4.1 Ͻ0.0001 Total stunning/remodeling score 2.5Ϯ3.1 0.5Ϯ2.3 Ͻ0.0001 5 day LVEF, % 45.4Ϯ9.6 49.1Ϯ9.2 0.01 30 day LVEF, % 52.9Ϯ10.8 46.1Ϯ8.9 Ͻ0.0001 5 day presence of MVO 52.5% (42/80) 59.5% (47/79) 0.37 5 day MVO, % of LV mass 0.30 [0.00, 1.67] 1.22 [0.00, 3.57] 0.06 5 day infarction, % of LV mass 21.1 [12.9, 29.2] 22.4 [12.9, 33.9] 0.28 5 day transmurality of infarction, % 71.9 [61.4, 79.6] 74.7 [65.9, 83.8] 0.08
Conclusions: Smaller area of microvascular obstruction 5 days after primary PCI for STEMI predicts better recovery of regional and global left ventricular function. Background: Cardioprotective effects of human atrial natriuretic peptide (hANP) in patients with acute myocardial infarction (MI) have been suggested by randomized clinical trials, however, no reports used surrogate endpoints offered by cardiac magnetic resonance (CMR), the current gold standard imaging modality. We evaluated the effects of hANP on left ventricular (LV) function in patients with reperfused acute MI using CMR. Methods: Forty-nine patients with first-time acute MI reperfused with percutaneous coronary intervention were studied. Continuous intravenous infusion of hANP was initiated before reperfusion therapy and continued for at least 2 days in 21 patients (hANP group). The remaining 28 patients received no adjunctive pharmacological therapy (no hANP group). CMR was performed at the acute phase and after 6 months (6M) to evaluate infarct size, LV end-diastolic and end-systolic volume and LV ejection fraction (EF). Results: We observed no difference in age, gender, coronary risk factors, maximum levels of creatine phosphokinase, time to reperfusion and baseline CMR parameters between the 2 groups. However, at 6M, a significant improvement in LVEF in hANP group was seen compared to no hANP group (baseline: 48.1 Ϯ 11.4% to 6M: 52.8 Ϯ 10.6% vs. baseline: 49.9 Ϯ 13.6% to 6M: 50.0 Ϯ 10.7%; p ϭ 0.015).
TCT-517

Effects Of Intravenous Human Atrial Natriuretic Peptide On Left Ventricular Function In Patients With Reperfused Acute Myocardial Infarction: An Assessment By Cardiac Magnetic Resonance Imaging
Conclusions:
These results assessed using CMR suggest that intravenous hANP infusion can improve LV systolic function in patients with reperfused acute MI.
TCT-518
Clinical Outcomes of Multiple Stent Implantation in patients with ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Jinhee Ahn 1 , Kwang Soo Cha 1 , Jeong Cheon Choi 1 , Jung Hyun Choi 1 , Jong Hyun Choi 1 , Taek Jong Hong 1 , Hye Yoon Jang 1 , Hye Won Lee 1 , Han Cheol Lee 1 1 Pusan National University Hospital, Busan, Korea, Republic of Background: Percutaneous coronary intervention (PCI) with adoption of coronary stents since 1994, is an established management for ST-segment elevation myocardial infarction (STEMI) and has been known relatively safe and effective resulting in better acute angiographic outcomes, reduction in the frequency of repeated stenosis or revascularization with proper antiplatelet agents. However, stent itself is related with major adverse cardiac events (MACE) depending on stent parameters such as length, diameter or structure materials under various clinical circumstances. In cases of long lesion, implantation of multiple stents is common in daily practice and the relationship between multiple stent implantation and MACE in acute myocardial infarction (MI) is shown by a few studies but data is lack in the setting of STEMI. The aim of this study is to compare clinical outcomes between single and multiple-stent implanted groups in Korean patients with STEMI undergoing primary PCI. Methods: Using data from Korea Acute Myocardial Infarction Registry (KAMIR; November 2005-January 2008), a total of 1,668 patients with STEMI who proven to have single culprit vessel disease on primary PCI were enrolled in this study. The patients were divided into two groups: single stent group (nϭ1,391, 83.4%) and multiple stent group (277, 16.6%).
Results:
The primary outcome, one-year cumulative incidence rate of MACE defined as composition of death, nonfatal MI, re-PCI or coronary artery bypass graft, was significantly higher in the multiple stent group (10.4% versus 16.7%, pϭ0.010), which was mainly due to increased target lesion revascularization (3.9% versus 9.4%, pϭ0.001). By multivariate logistic regression analysis, multiple stent implantation was remained as a prognostic factor for MACE (ORϭ1.590, 95% CI: 1.028-2.459, pϭ0.037). Coxproportional hazard model also showed implanted stent number is associated with MACE significantly (HRϭ1.900, 95% CI: 1.157-3.119, pϭ0.011).
Conclusions:
This study demonstrated that multiple stent implantation is associated with increased one-year cumulative incidence rate of MACE and is a predictor for clinical outcomes independent of stent length, diameter or type in Korean populations with STEMI.
TCT-519
Randomized study to assess the effect of ThRombus aspiration on flow area in STEMI patients: an Optical Frequency domain Imaging study (TROFI). Twoand Three-dimensional analysis of Six-month OFDI follow-up.
Background: Primary coronary intervention (PCI) with thrombectomy seems to reduce the thrombus burden measured with optical frequency domain imaging (OFDI), resulting in a better stent expansion and less late malapposition, when compared to PCI without thrombectomy. Methods: In a prospective multi-centre study, 141 patients with STEMI Ͻ12 hours from onset were randomized to either PCI with thrombectomy (TB: nϭ71) or without thrombectomy (nonTB: nϭ70), with blinding of the operator for the OFDI results. The primary endpoint was minimal flow area (Min FA) post-procedure assessed by OFDI, defined as: (Stent area ϩ incomplete stent apposition [ISA] area) -(intraluminal defect ϩ tissue prolapse area). Sample size was based on the expected difference of 0.72mm2 in MinFA. Fifty-one patients repeated invasive angiographic and OFDI follow-up at 6 months. Results: Baseline demographics, preprocedural QCA and procedural characteristics were well matched between the two groups. Immediately after stenting on OFDI, the average stent area, the amount of prolapse, intraluminal defect and ISA area were similar in the both groups. In the population with a serial OFDI follow-up at Baseline and 6M, the post-procedural minFA were numerically larger in TB than in non-TB, but the difference did not reach statistical significance (TB 6.05Ϯ2.18 vs. 5.61Ϯ2.06 mm2, pϭ0ϭ31). At 6 months, the mean ISA area was similar between two groups (TB 0.02Ϯ0.06 vs. non-TB 0.02Ϯ0.04 mm2, pϭ0.68). The percent coverage of struts was low but there were no differences between the groups (TB 83.86Ϯ9.91% vs. non-TB 84.04Ϯ14.72%).
Conclusions:
At 6M follow-up, there were no differences in the mean ISA area as well as %tissue coverage between the thrombectomy and non-thrombectomy group. Threedimensional presentation of intra-luminal masses at baseline and follow-up will be presented at the meeting.
TCT-520
Descriptive Study Of Patients With ST-elevation Myocardial Infarction Presenting With Out Of Hospital Cardiac Arrest
Fizzah Choudry 1 , Roshan Weerackody 1 , Andrew Wragg 1 , Peter Mills 1 , Ajay Jain 1 1 Barts and the London, London, United Kingdom Background: ST elevation myocardial infarction (STEMI) complicated by out of hospital cardiac arrest (OOHCA) is associated with significant mortality. Small observational studies have shown survival benefit with primary percutaneous coronary intervention (pPCI) in this setting. We sought to investigate morbidity and mortality outcomes in this patient cohort. Methods: Between January 2008 and October 2011, STEMI admissions to a regional cardiac centre were retrospectively analysed. 122 patients with OOHCA in the context of STEMI were identified. Clinical data was collected from the UK Myocardial Ischaemia TUESDAY, OCTOBER 23, 8:00 AM-10:00 AM 
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